Article

You have free access to this content

Oral antidiabetic treatment in patients with coronary disease: Time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up

  1. Enriqe Z. Fisman M.D.1,*,
  2. Alexander Tenenbaum M.D., Ph.d.1,
  3. Yehuda Adler M.D.1,
  4. Michael Motro M.D.1,
  5. Valentina Boyko M.S.2,
  6. Michal Benderly M.S.2,
  7. Aharon Friedensohn M.D.2,
  8. Mira Kohanovski M.D.2,
  9. Rene Rotzak M.D.2,
  10. Hanan Schneider M.D.2,
  11. Solomon Behar M.D.2

Article first published online: 7 AUG 2009

DOI: 10.1002/clc.4960240210

Issue

Clinical Cardiology

Clinical Cardiology

Volume 24, Issue 2, pages 151–158, February 2001

Additional Information

How to Cite

Fisman, E. Z., Tenenbaum, A., Adler, Y., Motro, M., Boyko, V., Benderly, M., Friedensohn, A., Kohanovski, M., Rotzak, R., Schneider, H. and Behar, S. (2001), Oral antidiabetic treatment in patients with coronary disease: Time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol, 24: 151–158. doi: 10.1002/clc.4960240210

Author Information

  1. 1

    Cardiac Rehabilitation Institute

  2. 2

    the Bezafibrate Infarction Prevention Coordinating Center, Neufeld Cardiac Research Institute, the Chaim Sheba Medical Center, affiliated to the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

*Cardiac Rehabilitation Institute Chaim Sheba Medical Center 52621 Tel-Hashomer, Israel

Publication History

  1. Issue published online: 7 AUG 2009
  2. Article first published online: 7 AUG 2009
  3. Manuscript Accepted: 12 MAY 2000
  4. Manuscript Received: 11 JAN 2000

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (838K)

References

  • 1
    Hamby R, Sherman L., Mehta J., Aintablian A., Reappraisal of the role of the diabetic state in coronary artery disease. Chest 1976; 70: 251–257
  • 2
    The DCCT Trials: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986
  • 3
    Pyorala K., Pedersen TR, Kjekshus J., Faergeman O., Olsson AG, Thorgeirsson G., the Scandinavian Simvastatin Survival Study (4S) Group: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997: 20: 614–620
  • 4
    UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). Br Med J 1998: 317: 713–720
  • 5
    Tenenbaum A., Fisman EZ, Boyko V, Godbourt U., Graff E., Shemesh J., Shotan A., Reicher-Reiss H., Behar S., Motro M., Hypertension in diet versus pharmacologically treated diabetics. Mortalits over a 5-year follow-up. Hypertension 1999: 33: 1002–1007
  • 6
    Klimt CR, Knatterud GL, Meinert CL, Prout TE, The University Group Diabetes Program: A study of the effect of hypoglycemic agents on vascular complications inpatients with adult-onset dia. I. Design, and baseline characteristics II. Mortality results. Diabetes 1970: 19 (suppl 2): 747–830
  • 7
    Smits P., Thien T., Cardiovascular effects of sulphonylurea derivatives. Implication for the treatment of NIDDM? Diabetologia 1995: 38: 116–121
  • 8
    Brady PA, Terzic A., The sulfonylurea controversy: More questions from the heart. J Am Coll Cardiol 1998; 31: 950–956
  • 9
    Innerfield RJ, Metformin-associated mortality in U.S. studies. N Engl J Med 1996: 1611–1613
  • 10
    Misbin RI, Green L., Stadel BV, Gueriguian JL, Gubbi A., Fleming GA, Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998; 338: 265–266
  • 11
    Fisman EZ, Tenenbaum A, Benderly M., Goldbourt U., Behar S., Motro M., Antihyperglycemic treatment in diabetics with coronary disease: Increased metformin-associated mortality over a 5-year follow-up. Cardiology 1999: 91: 195–202
  • 12
    Consensus Statement, The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1996 (suppl I): 19: S54–S61
  • 13
    Nathan DM, Some answers, more controversy, from UKPDS. Lancet 1998; 352: 832–833
  • 14
    U.K. Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–865
  • 15
    Goldbourt U., Behar S, Reicher-Reiss H., Agmon J., Kaplinsky E., Graff E., Kishon Y, Caspi A., Weisbort J., Mandelzweig L., Abinader E., Aharon L., Braun S., David D., Flich M., Friedman Y., Kristal N., Leil N., Markiewicz W., Marmor A., Palanl A., Pelled B, Rabinowitz B., Reisin L., Roguin N., Rosenfeld T., Schlesinger Z., Sclarovsky S., Sherf L., Tzivoni D., Zahavi I., Zion M., Brunner D., for the Bezafibrate Infarction Prevention Study Group: Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 1993: 71: 909–915
  • 16
    Benderly M, Graff E, Reicher-Reiss H., Behar S., Brunner D., Goldbourt U., Fibrinogen is a predictor of mortality in coronary artery disease patients. Arterioscler Thromb Vase Biol 1996: 16: 351–356
  • 17
    International Classification of Diseases. Clinical Modification. 9th revision, vol. I. Ann Arbor: Edwards Bros., 1981
  • 18
    SAS Institute Inc. SAS/STAT User s Guide, version 6, 4th edition, volume 2. Cary, N.C.: SAS Institute Inc., 1987
  • 19
    Yaari S, Goldbourt U., An SAS program for evaluating person-years of risk on cohort studies. Comp Biol Med 1989; 19: 353–359
  • 20
    SAS/STAT Software: Changes and Enhancements, release 6.07, p. 620. SAS technical report P-229. Cary, N.C.: SAS Institute Inc., 1992
  • 21
    Nathan DM, Meigs J., Singer DE, The epidemiology of cardiovascular disease in type 2 diabetes mellitus: How sweet it is… or is it? Lancet 1997: 350 (suppl l): 4–9
  • 22
    U.K. Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853
  • 23
    Duncker DJ, van Zon NS, Altman JD, Pavek DJ, Bache RJ, Role of K+ ATP channels in coronary vasodilation during exercise Circulation 1993: 88: 1245–1253
  • 24
    Cole WC, McPherson CD, Sontag D., ATP-regulated K+ channels protect the myocardium against ischemia/reperfusion damage. Circ Res 1991; 69: 571–581
  • 25
    Toombs CF, McGee DS, Johnston WE, Vinten-Johansen J., Myocardial protective effects of adenosine. Infarct size reduction with pretreatment and continued receptor stimulation during ischemia Circulation 1992; 86: 986–994
  • 26
    Pogatsa G., Koltai ZM, Ballagi-Pordany G., Influence of hypoglycemic sulfonylurea compounds on the incidence of ventricular ectopic beats in non-insulin-dependent diabetic patients treated with digitalis. Curr Ther Res 1993; 53: 329–339
  • 27
    Grover GJ, Sleph PC, Dzwonick BS, Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interactions with adenosine A1 -receptors Circulation 1992: 86: 1310–1316
  • 28
    Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A., Holmes DR, Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33: 119–124
  • 29
    Klepzig H., Kober G, Matter C., Luus H., Schneider H., Boedeker KH, Kiowski W., Amann FH, Gruber D, Harris S., Burger W., Sulfonylureas and ischemic preconditioning. A double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999; 20: 439–446
  • 30
    DeFronzo RA, Barzilai R., Simonson DC, Mechanism of metformin action in obese and lean noninsuline-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294–1301
  • 31
    Adams JF, Clark JS, Ireland JT, Kesson CM, Watson WS, Mal-absorption of vitamin B12 and intrinsic factor secretion during biguanide therapy. Diabetologia 1983; 24: 16–18
  • 32
    Mayer EL, Jacobsen DW, Robinson K., Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996: 27: 517–527
  • 33
    Nygard O., Nordrehaug JE, Refsum H., Ueland PM, Farstad M., Vollset SE, Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230–236
  • 34
    DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group, Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med 1995; 333: 541–549
  • 35
    Goldner MG, Knatterud GL, Prout TE, Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. III. Clinical implication of UGDP results. J Am Med Assoc 1971: 218: 1400–1410
  • 36
    U.K. Prospective Diabetes Study Group: UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998: 21: 87–92
  • 37
    Giugliano D., Does treatment of noninsulin-dependent diabetes mellitus reduce the risk of coronary heart disease? Curr Opin Lipidol 1996; 7: 227–233
  • 38
    Marchetti P., Navalesi R., Pharmacokinetic-pharmacodynamic relationships of oral hypoglycemic agents: An update. Clin Pharma-cokinet 1989; 16: 100–128
  • 39
    Arauz-Pacheco C., Rios JM, Raskin P., Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy. Am J Med 1990; 89: 811–813
  • 40
    Dunn CJ, Peters DH, Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995: 49: 721–749
  • 41
    Gu K., Cowie CC, Harris MI, Diabetes and decline in heart disease mortality in US adults. J Am Med Assoc 1999; 281: 1291–1297
Get PDF (838K)